Effect of levodopa on cochlear mechanics and efferent auditory system of Parkinson’s disease individuals
Effect of levodopa on cochlear mechanics and efferent auditory system of Parkinson’s disease individuals
Marcia da Silva Lopes; Ailton de Souza Melo; Ana Paula Corona; Ana Caline Nóbrega
Abstract
Purpose: To evaluate the effect of levodopa on cochlear dynamics and on the medial olivocochlear efferent pathway of idiopathic Parkinson’s disease (PD) individuals. Methods: Individuals with and without PD, followed at a University Hospital, were submitted to Distortion Product Otoacoustic Emissions (DPOAE) and DPOAE Inhibitory Effect (OAEIE) in the presence of contralateral noise. Correlation measures between DPOAE and OAEIE results with Hoehn&Yahr (H&Y) stage, daily dose of levodopa and PD diagnosis period were established. Furthermore, electroacoustic measures were compared between individuals without and those with PD, stratified by dose of levodopa daily administered. Results: Weak negative correlation between DPOAE amplitude and daily dose of levodopa was found, as well positive correlations between EIEOA with daily dose of levodopa and time of PD diagnosis, respectively. Higher DPOAE amplitude was found in individuals with PD using daily doses of levodopa ≤ 600 milligrams when compared to individuals without PD and those with PD using higher doses. EIEOA was lower in individuals using doses ≤ 600 milligrams, when compared to the other groups. Conclusion: Daily doses of levodopa up to 600 mg / day increase the cochlear mechanical-transducer responses in 2 and 3 kHz frequencies, while the action of olivocochlear efferent systems is reduced in this region
Keywords
Resumo
Objetivo: Analisar o efeito da levodopa na dinâmica coclear, bem como na via eferente olivococlear medial de indivíduos com doença de Parkinson idiopática (DP). Método: Indivíduos com e sem DP, acompanhados em um hospital universitário, realizaram a pesquisa das emissões otoacústicas por produto de distorção (EOAPD) e do efeito inibitório das EOAPD (EIEOA) na presença de ruído contralateral. Foram estabelecidas as medidas de correlação entre os resultados das EOAPD e do EIEOA com estágio Hoehn&Yahr (H&Y), dose diária de levodopa e tempo de diagnóstico da DP. Além disso, as medidas eletroacústicas foram comparadas entre os indivíduos sem DP e com DP, estratificados de acordo com a dose de levodopa administrada diariamente. Resultados: Foi identificada correlação fraca e negativa entre a amplitude das EOAPD com a dose diária de levodopa e correlações positivas, de força moderada e fraca, entre o EIEOA com a dose diária de levodopa e o tempo de diagnóstico da DP, respectivamente. A amplitude das EOAPD foi maior nos indivíduos com DP em uso de levodopa ≤ 600 miligramas quando comparada à de indivíduos sem DP e com DP, em uso de dose superior. Já o EIEOA foi menor nos indivíduos em uso de doses ≤ 600 miligramas, quando comparado aos demais grupos. Conclusão: Doses diárias de levodopa iguais ou inferiores a 600 mg/dia aumentam as respostas mecanotransdutoras cocleares nas frequências de 2 e 3 kHz, enquanto que a ação dos sistemas eferentes olivococleares é reduzida nesta região.
Palavras-chave
Referências
1 Limongi JCP. Conhecendo melhor a doença de Parkinson: uma abordagem multidisciplinar com orientações práticas para o dia-a-dia. São Paulo: Plexus; 2001. Principais sintomas, causas e formas clínicas; p. 13-35. [ Links ]
2 Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5-15. http://dx.doi.org/10.1111/j.1468-1331.2012.03866.x . PMid:23279439. [ Links ]
3 Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson’s disease. Neurology. 1998;50(6, Supl 6):S11-4. http://dx.doi.org/10.1212/WNL.50.6_Suppl_6.S11 . PMid:9633680. [ Links ]
4 Sharma S, Singh S, Sharma V, Singh VP, Deshmukh R. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies. Biomed Pharmacother. 2015;70:283-93.http://dx.doi.org/10.1016/j.biopha.2015.01.029 . PMid:25776513. [ Links ]
5 Fahn S. The history of dopamine and levodopa in the treatment of Parkinson’s disease. Mov Disord. 2008;23(S3, Supl 3):S497-508. http://dx.doi.org/10.1002/mds.22028 . PMid:18781671. [ Links ]
6 Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, et al. The natural history of treated Parkinson’s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82(10):1112-8.http://dx.doi.org/10.1136/jnnp.2011.240366 . PMid:21593513. [ Links ]
7 Lamas V, Juiz JM, Merchán MA. Ablation of the auditory córtex results in changes in the expression of neurotransmission related mRNAs in the cochlea. Hear Res. 2017;346:71-80.http://dx.doi.org/10.1016/j.heares.2017.02.011 . PMid:28216123. [ Links ]
8 Toro C, Trapani JG, Pacentine I, Maeda R, Sheets L, Mo W, et al. Dopamine modulates the activity of sensory hair cells. J Neurosci. 2015;35(50):16494-503. http://dx.doi.org/10.1523/JNEUROSCI.1691-15.2015 . PMid:26674873. [ Links ]
9 Wang L, Li J, Yu L, Li X. Regulation of dopamine D2 receptors in the guinea pig cochlea. Acta Otolaryngol. 2014;134(7):738-43. http://dx.doi.org/10.3109/00016489.2014.899712 . PMid:24807851. [ Links ]
10 Garrett AR, Robertson D, Sellick PM, Mulders WH. The actions of dopamine receptors in the guinea pig cochlea. Audiol Neurootol. 2011;16(3):145-57. http://dx.doi.org/10.1159/000316674 . PMid:20668375. [ Links ]
11 Folmer RL, Vachhani JJ, Theodoroff SM, Ellinger R, Riggins A. Auditory processing abilities of parkinson’s disease patients. BioMed Res Int. 2017;2017:2618587. http://dx.doi.org/10.1155/2017/2618587 . PMid:28546963. [ Links ]
12 Vitale C, Marcelli V, Allocca R, Santangelo G, Riccardi P, Erro R, et al. Hearing Impairment in Parkinson’s disease: expanding the nonmotor phenotype. Mov Disord. 2012;27(12):1530-5.http://dx.doi.org/10.1002/mds.25149 . PMid:23032708. [ Links ]
13 Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4.http://dx.doi.org/10.1136/jnnp.55.3.181 . PMid:1564476. [ Links ]
14 Lautenschlager L, Tochetto T, Costa MJ. Reconhecimento de fala em presença de ruído e suas relações com a supressão das emissões otoacústicas e o reflexo acústico. Rev Bras Otorrinolaringol (Engl Ed). 2011;77(1):115-20. [ Links ]
15 Kim S, Frisina DR, Frisina RD. Effects of age on contralateral suppression of distorcion product otoacoustic emissions in human listeners with normal hearing. Audiol Neurootol. 2002;7(6):348-57.http://dx.doi.org/10.1159/000066159 . PMid:12401966. [ Links ]
16 Pisani V, Sisto R, Moleti A, Di Mauro R, Pisani A, Brusa L, et al. An investigation of hearing impairment in de-novo Parkinson’s disease patients: a preliminary study. Parkinsonism Relat Disord. 2015;21(8):987-91.http://dx.doi.org/10.1016/j.parkreldis.2015.06.007 . PMid:26071125. [ Links ]
17 Ashmore J. Cochlear outer hair cell motility. Physiol Rev. 2008;88(1):173-210.http://dx.doi.org/10.1152/physrev.00044.2006 . PMid:18195086. [ Links ]
18 Lichtenhan JT, Wilson US, Hancock KE, Guinan JJ Jr. Medial olicochlear efferent reflex inhibition of human cochlear nerve responses. Hear Res. 2016;333:216-24. http://dx.doi.org/10.1016/j.heares.2015.09.001 . PMid:26364824. [ Links ]
19 Nouvian R, Eybalin M, Puel JL. Cochlear efferents in developing adult and pathological conditions. Cell Tissue Res. 2015;361(1):301-9. http://dx.doi.org/10.1007/s00441-015-2158-z . PMid:25810366. [ Links ]
20 Ruel J, Nouvian R, D’Aldin CG, Pujol R, Eybalin M, Puel J-L. Dopamine inhibition of auditory nerve activity in the adult mammaliam cochlea. Eur J Neurosci. 2001;14(6):977-86. http://dx.doi.org/10.1046/j.0953-816x.2001.01721.x . PMid:11595036. [ Links ]
Submetido em:
22/11/2017
Aceito em:
04/05/2018
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email